|
What’s Inside: Bay Area Election Results; 2022 Economic Impact Report; South San Francisco Holiday Market; Caltrain Temporarily Reduces Service; Plan Ahead for #JPM23; and more.
|
Support Local Businesses at the South San Francisco Holiday Market
Join us for an outdoor holiday market to support local South San Francisco small businesses on December 13 from noon to 5 p.m. All vendors have come through the Renaissance Entrepreneurship Center in South San Francisco, which helps thousands of individuals achieve personal, financial, and social transformation through the power of small business. Find everything from plants to luxury candles, jewelry and handmade soaps. Details here.
Just Released: 2022 Life Science Economic Impact Report
Biocom California is pleased to announce the launch of our 2022 Life Science Economic Impact Report — a refreshed analysis and vital barometer of the profound impact that the life science industry has in California. This 52-page report created in partnership with Deloitte reveals how California continues to be the leading innovation hub for life sciences, providing more than 400,000 jobs in the state and generating $376 billion in total economic output. The nine counties of the Bay Area alone represent a total workforce of ~4.2 million people, with 146,000 of them directly employed by life science companies. Life science jobs in the Bay Area pay an average of $148,167 and represent a regional
economic impact of $150.9 billion. Download Bay Area Fact Sheet.
We’re Hiring!
We are currently hiring for a Program Manager for our Bay Area office. Visit the posting here for more information and the application process.
|
|
|
Welcome New Bay Area Members
|
|
|
|
|
|
|
Leadership and Service Changes at Caltrain
Last month, Caltrain named 20-year employee Michelle Bouchard as the first permanent executive director of the railroad. Caltrain is currently electrifying it’s fleet, which will result in temporary reduced service levels between December 5 and December 18.
Bay Area Election Results
For our full election recap for the Bay Area click here. Don’t forget to subscribe to our policy newsletter for the latest updates from our advocacy team.
Biocom California Extends Thanks to South San Francisco City Manager Mike Futrell
Biocom California extends a heartfelt thanks to outgoing South San Francisco City Manager Mike Futrell for his many years of supporting the life science industry in the city. Last month, Futrell announced he has accepted a new role as City Manager of Riverside starting in January. Futrell has been a standout champion for life sciences during his tenure. Under his leadership, South San Francisco developed into the “Biotechnology Capital of the World,” home to over 250 life science companies.
Spotlight on Fremont Event Draws 100 Attendees
Biocom California’s “Spotlight” series draws attention to localities that are booming or upcoming life science hubs and what has helped life science grow in that area. On December 7 we held the latest in the series focused on the City of Fremont. A large crowd gathered at the new Fremont Downtown Event Center to hear the latest from companies and community leaders.
San Mateo County Chamber Hosts Biocom California’s Team
Biocom California staff spoke at the San Mateo County Chamber Economic Development Committee meeting on December 6 for a panel focused on the life sciences. Bay Area Executive Director Michelle Nemits presented our newly released Economic Impact Report, and Sr. Director of Regional Policy and Government Affairs Melanie Cohn focused on what local governments can do to encourage life science growth.
Our Fourth Annual Facilities Reception
Our fourth annual Bay Area Facilities Reception drew a large crowd to EmeryStation on December 8. This event is an opportunity for Facilities and Environmental Health and Safety professionals to mingle in a relaxed and festive environment. Thanks to all attendees for joining us and to our sponsors Wareham, SBM, Veolia, Gidel & Kocal, and Xiltrix. If you’re interested in joining our Facilities/EH&S Committee, contact Melanie Cohn.
In Other News:
- Biocom California’s President and CEO Joe Panetta was interviewed by KQED about life science industry growth in the Bay Area despite a cooling economy.
- Some counties (San Francisco, Marin) are facing a “builder’s remedy,” which would allow developers to build at will until counties have a plan in place to meet their state mandated housing goals.
- Bay Area transit systems, BART, Muni, and Caltrain all reported budget deficits that could result in service cuts in coming years.
- Water users are asked to continue conserving as storms don’t remedy drought.
|
|
|
|
Planning Ahead for #JPM23: Need Meeting Space?
Finding a dedicated space to connect with business colleagues and prospects during JPM week can be challenging. We’re helping our members by providing complimentary meeting space at Hotel Zeppelin, just steps away from the conference. Meeting rooms are available to Biocom California Members for
30 minutes per company per day. Members can meet with non-members, but the room must be booked by a Biocom California member. Book your meeting space today.
Join Us to Kick Off JPM 2023 in Style
Hosted by AZBio, Biotechnology Innovation Organization, Biocom California, BioNJ, Helsinn, Lonza, MichBio, NewYorkBIO, and others, the State Bio Friends Reception kicks off the largest annual gathering of healthcare innovators and healthcare investors in the world. This is a private reception for members of hosted life science associations and is invite-only, and will take place on January 8, 2023, at The Marker Hotel from 4 p.m. to 7 p.m. Use promo code ‘ Biocom4CA’ when registering.
JPM 2023 Cocktail Reception Hosted by BioMed Realty and Biocom California
Please join BioMed Realty and Biocom California for an evening of great company and food at The Clift Royal Sonesta Hotel’s historic Redwood Room on January 9, 2023, from 6 p.m. to 9 p.m. Best of all, we will be showing the NCAA College Football playoff game on a wide-screen TV. Register today.
JPM 2023: Biotech Showcase
Biotech Showcase is an investor and networking conference devoted to providing private and micro-mid-cap biotech companies an opportunity to present to and meet with investors and biopharma executives. Biotech Showcase will be in San Francisco in-person January 9–11, 2023, and digitally January 18–19, 2023, on partneringON. In-person attendees are also welcome to join the virtual conference days and schedule one-to-one meetings. Biocom California members can use the promo code supBIOCOM2023 to receive $200 off registration.
LifeLines: Insights from Biocom’s Capital Development Team
Harrison Shapira, Partnering Manger on our Capital Development team, writes on the challenging circumstances early-stage companies face. Looking at both the public and private markets, as well as present economic conditions, what can company executives do to extend the runway and endure the unfavorable conditions? This article provides insights from industry experts and shares ideas executives can employ as they look to raise capital, partner and navigate the next three to 18 months.
Apply to Showcase Your Company at Our Global Partnering Conference
Is your company seeking funding and/or strategic business partners to help you grow? Apply today to stream your presentation at Biocom’s Global Life Science Partnering Conference, which happens in San Diego February 28 to March 2, 2023. Presenting at the conference is a unique opportunity for life science companies looking to raise money and build collaborations with investors and potential strategic partners. Applications are due January 13, 2023.
|
|
|
|
Leveraging Your Leadership
The 15th Anniversary Edition of Leveraging Your Leadership from The Leadership Edge is a three-day virtual program for life science executives, vice presidents, and directors who have a strong management foundation with a track record of success and are looking to build the leadership skills and capabilities needed to succeed in today’s ever-changing life sciences industry. Courses are available March 15, 2023, through April 19, 2023. Register by March 1, 2023. Biocom California members enjoy $500 off, no code is necessary. Register here.
|
|
|
|
Thermo Fisher Scientific’s Financial Solutions Can Help Stretch Lab Budgets
Innovation often comes with a high price tag. Thankfully, Thermo Fisher Scientific is making it easier than ever to maximize your resources and enable your success through their Financial Solutions program. For a limited time, they are offering interest rates as low as 3 percent on all Thermo Fisher products and services. Even better, payments do not commence until your equipment is fully installed. With the market prime rate currently 6.25 percent, low-cost financing like this is hard to come by. This limited-time, fixed-rate promotion is accepting applications until December 31, 2022. Apply here today.
|
|
|
|
Cell & Gene Therapy Committee
The Biocom California Cell & Gene Therapy Committee will meet on January 19, 2023 from 4 p.m. to 6 p.m. The expert panel, led by committee co-chairs Jens Vogel, Global Head of Biotech at Bayer, and Jeff Bluestone, CEO at Sonoma Biotherapeutics, will discuss “The CMC Bottleneck in Cell Therapy.” This program will take place live in South San Francisco and be simulcast to a live gathering in both San Diego and Los Angeles. You must attend in person to access the content. All locations will offer live engagement and networking. Details and registration here.
|
|
|
Member News
|
Allogene Therapeutics hosts an R&D showcase features hematologic and solid tumor advances across its AlloCAR T platform. Amyris Inc. announced record consumer sales performance during this year’s Black Friday sales week for its Biossance skin care line.
Berkeley Lights launches the Opto Memory B Discovery Rabbit workflow, expanding the diversity of antibodies customers can discover on its Beacon platform.
Bolt Biotherapeutics is pioneering a new approach to cancer immunotherapy with immune-stimulating antibody conjugates (ISACs).
Caribou Biosciences announces the FDA granted Regenerative Medicine Advanced Therapy (RMAT) and fast track designations to CB-010, an allogeneic anti-CD19 CAR-T cell therapy. Rachel Haurwitz, Caribou’s CEO, was also recently named one of the Most Admired CEOs by the San Francisco Business Times.
Catalent Inc. announced a new license agreement with Exelixis under which Catalent’s Redwood Bioscience subsidiary will grant Exelixis an exclusive license to three target programs with lead antibody and/or ADC candidates.
The California Institute for Regenerative Medicine (CIRM) funds clinical trials targeting solid tumors and to make kidney transplants easier for patients.
Eureka Therapeutics announces license with the National Cancer Institute to advance GPC2 ARTEMIS T cell therapy for neuroblastoma.
4D Molecular Therapeutics releases interim clinical data from on-going Phase 1/2 clinical trial of intravitreal 4D-150 for wet age-related macular degeneration (wet AMD).
Invitae launches rare patient network for pediatric patients with rare neurodevelopmental diseases.
Kyverna Therapeutics receives FDA Clearance of IND for KYV-101, a novel fully human CD19 CAR T-cell therapy for lupus nephritis.
Ligand Pharmaceuticals completes the expected tax-free spin-off of its OmniAb antibody discovery business, OmniAb Inc., an independent publicly traded company.
Nutcracker Therapeutics presented the first set of preclinical data for its lead oncology mRNA therapeutic, NTX-250, at the 37th annual Society for Immunotherapy of Cancer meeting.
Pivot Bio joins the Agriculture Innovation Mission for Climate (AIM for Climate) as an Innovation Sprint Partner, committing $291 million in product development funding over four years.
Tenaya Therapeutics received orphan drug designation for TN-401, its gene therapy for genetic arrhythmogenic right ventricular cardiomyopathy.
TrueBinding shares results of TB006 Phase 1b/2 placebo controlled proof-of-concept trial showing improvement on the primary cognition and function endpoint in patients with mild to severe Alzheimer’s disease.
Upside Foods got a safety nod from the FDA for its cell-cultured meat, bringing the company one step closer to selling its products in the U.S.
Vaxart receives funding from the Bill & Melinda Gates Foundation for a new study of its norovirus vaccine candidate for breastfeeding mothers and infants.
Submit your news here.
|
|
|
Biocom California | Bay Area
Biocom California is the largest, most experienced leader and advocate for California’s life science sector. Our South San Francisco office aims to build the networks that are critical to growth in this thriving regional ecosystem. Our targeted programs and customized services are tailored to the specific needs of the Bay Area region. We work on behalf of more than 1,700 members to drive public policy, build an enviable network of industry leaders, create access to capital, introduce cutting-edge STEM education programs, and create robust value-driven purchasing programs.
|
|
|
